Saruparib is a new pill that blocks PARP1, a protein cancer cells use to repair DNA. Laboratory and early‑phase studies indicated 60 mg once a day as the recommended dose. Adding saruparib might hold the cancer in check for longer.  Phase 3 Trial of Saruparib...